viewAIM ImmunoTech Inc.

Full interview: Hemispherx Biopharma releases 'well tolerated' data for Ampligen ovarian cancer treatment

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated."

Equels explains the optimal way to administer Ampligen in ovarian cancer patients is into the intraperitoneal cavity near the tumor site, which has been done, and the company has moved forward with Phase II studies.

Quick facts: AIM ImmunoTech Inc.

Price: 0.4851 USD

Market: NYSE
Market Cap: $2.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...



Hemispherx Biopharma makes progress with Phase 2 clinical trial to treat...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Proactive Investors the biopharma has taken a key step forward in its Phase 2 clinical trial after it announced that the first patient has been treated with its flagship drug Ampligen. Equels says this study looks at the...

on 06/20/2019

2 min read